Safe Chain Solutions, a wholesale drug distributor, failed to verify suspect Biktarvy and bought from unauthorized trading partners.
What happened
FDA inspected Safe Chain's wholesale drug distribution facility in Cambridge, Maryland, from April 11 to May 11, 2022. FDA found the company lacked adequate systems and records to verify and investigate suspect products, did not respond to an illegitimate-product notification, and bought prescription drugs from unauthorized trading partners. The letter says multiple Biktarvy lots Safe Chain distributed contained different tablets than the label stated.
What FDA found
Safe Chain lacked adequate written systems to identify suspect product, investigate it, handle notifications, and keep records as DSCSA requires.
FD&C Act Section 582(c)(4)(A) & (B)Safe Chain bought prescription drugs from Gentek and Boulevard 9229 LLC, which were not authorized trading partners.
FD&C Act Section 582(c)(3)Safe Chain could not provide records showing how suspect Biktarvy lots were quarantined, investigated, or disposed of.
FD&C Act Section 582(c)(4)(A)(iii)Safe Chain did not show that it identified, quarantined, or investigated Biktarvy lot CDGXKA after Gilead said it was illegitimate.
FD&C Act Section 582(c)(4)(B)(iii)
What FDA wants
FDA tells Safe Chain to correct the violations promptly and respond in writing within 15 working days, specifying what it has done and how it will prevent recurrence; if it cannot finish, it must give reasons and a completion schedule.
Who should pay attention
- wholesale drug distributors and their compliance teams
- pharmacies and health systems buying from distributors
- brands and manufacturers whose products move through secondary wholesalers
This is a summary. Read the original letter on fda.gov.